Trexquant Investment LP Invests $425,000 in Oric Pharmaceuticals, Inc. $ORIC

Trexquant Investment LP purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 76,093 shares of the company's stock, valued at approximately $425,000. Trexquant Investment LP owned approximately 0.11% of Oric Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Vivo Capital LLC lifted its position in Oric Pharmaceuticals by 62.8% in the first quarter. Vivo Capital LLC now owns 2,080,450 shares of the company's stock valued at $11,609,000 after acquiring an additional 802,632 shares during the last quarter. Nuveen LLC acquired a new position in shares of Oric Pharmaceuticals in the 1st quarter valued at $935,000. Sphera Funds Management LTD. boosted its holdings in shares of Oric Pharmaceuticals by 112.8% in the 4th quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company's stock valued at $2,205,000 after purchasing an additional 144,817 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Oric Pharmaceuticals by 16.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock valued at $5,788,000 after purchasing an additional 103,237 shares during the last quarter. Finally, NEA Management Company LLC increased its stake in Oric Pharmaceuticals by 4.4% during the 4th quarter. NEA Management Company LLC now owns 1,566,081 shares of the company's stock worth $12,638,000 after buying an additional 66,081 shares during the period. Institutional investors and hedge funds own 95.05% of the company's stock.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC traded down $0.08 during midday trading on Friday, reaching $10.78. 906,238 shares of the company's stock traded hands, compared to its average volume of 841,458. Oric Pharmaceuticals, Inc. has a one year low of $3.90 and a one year high of $14.67. The stock has a 50 day moving average of $10.43 and a 200 day moving average of $8.18. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -5.70 and a beta of 1.63.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). Sell-side analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Insider Buying and Selling at Oric Pharmaceuticals

In related news, Director Angie You acquired 26,597 shares of the stock in a transaction dated Friday, June 20th. The stock was bought at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the purchase, the director directly owned 26,597 shares of the company's stock, valued at $249,745.83. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total value of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares in the company, valued at approximately $717,328.50. This represents a 32.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.82% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ORIC. Zacks Research raised shares of Oric Pharmaceuticals to a "hold" rating in a research note on Tuesday, August 12th. JPMorgan Chase & Co. decreased their price objective on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. HC Wainwright reduced their target price on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Finally, LADENBURG THALM/SH SH started coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, July 8th. They issued a "buy" rating and a $15.00 price target on the stock. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $17.29.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.